Gordonmd Global Investments LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Gordonmd Global Investments LP
CRD #316751
SEC #801-128434
CIK #0002039349
AUM 322.3 M (2026-03-26)
Employees 7 (71% Investors, 0% Brokers)
Fees
Minimum
Phone213-304-6199
Address9460 Wilshire Blvd
Beverly Hills, CA 90212
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($M)
3502802101407002010201520212027
Fees and Compensation — Form ADV Part 2A (3/26/2026) [Brochure]
Item 5: Fees and Compensation

The governing documents of each Fund set forth in detail the fee structure relevant to such Fund.

GordonMD typically receives compensation from fees based on a percentage of assets under
management, and Performance-Based Compensation. As discussed below, GordonMD will also
be reimbursed for certain fees or expenses, in each case, as disclosed in each Fund’s governing
documents. See the sections below on Management fees and Performance-Based Compensation
for further details. Investors should review Fund documents detailing all fees and expenses
incurred by the Funds to fully understand the total amount of fees and expenses to be paid by a
Fund.

GordonMD may negotiate fees and waive all or a portion of the fees paid by investors in the Funds.
GordonMD may, in its discretion, enter into different fee arrangements with different Funds or

investors in the Funds for the same investment management services, including the Firm’s
Employees and affiliates.

Management fees payable by a Fund are generally deducted from cash held by such Fund in
accordance with such Fund’s governing documents.

The fee schedules for the Funds are described in detail in each Fund’s offering memorandum.

Investment Management Fees
With respect to Fund’s that employ a public equity strategy (GordonMD Long Biased Master
Fund, GordonMD Long Biased Fund LP, and GordonMD Long Biased Offshore Fund Ltd),
GordonMD receives an asset-based quarterly management fee, paid in advance, equal to 1.5% of
the value each Limited Partner’s Basic Capital Account of the net assets of such Public Equity Fund,
and 2.0% of the value of each Limited Partner’s Designated Capital Accounts of the net assets of
such designated investments (the “Management Fee”). GordonMD may, in its sole discretion,
waive or modify the Management Fee for any investors, including without limitation, investors that
are members, principals, Employees or affiliates of Adviser and its respective affiliates, relatives or
entities of such persons and for certain strategic or large investors.

With respect to Funds that employ a private equity strategy (GordonMD PE Fund LP, GordonMD
PE Offshore Feeder Fund LP, GordonMD PE Fund II LP, and Gordon SPV I LLC), GordonMD
receives an asset-based quarterly Management Fee, payable in advance, equal to 2% per annum of
invested capital of such Private Equity Fund. GordonMD may, in its sole discretion, waive or modify
the Management Fee for any investors, including without limitation, investors that are members,
principals, Employees or affiliates of Adviser and its respective affiliates, relatives or entities of such
persons and for certain strategic or large investors.

Performance-Based Compensation
GordonMD is paid performance-based compensation (“Performance-Based Compensation”) by
the Fund investors, which is compensation that is based on a share of capital gains on or capital
appreciation of the assets of the Fund. The performance-based compensation is generally 20% of
the net profits of the assets within the Funds subject to a loss carryforward provision. GordonMD
may waive or modify the Performance-Based Compensation for any investors, including without
limitation, investors that are members, principals, Employees or affiliates of GordonMD or its
respective affiliates, relatives or entities of such persons and for certain strategic or large investors.

Expenses
In addition to bearing the Management Fee and Performance-Based Compensation, if any, the Funds
also are subject to other expenses related to their investments and operations, such as (i) all
investment-related costs and expenses (i.e., expenses that, in the General Partner’s sole discretion,
are related to the investment of the Funds’ assets, whether or not such investments are
consummated), including commissions and charges, clearing and settlement charges, option
premiums and custodial and service fees, research-related expenses (including research-related
travel expenses with respect to conferences, capital raising, including travel and lodging related
thereto or otherwise), fees and expenses relating to consultants, including healthcare-related
consultants and physician networks (and their expert fees and/or lobbyist fees), and expenses

relating to attorneys, brokers or other professionals or advisors who provide research, advice or
due diligence services with regard to investments; (ii) fees and expenses related to portfolio
exposure and performance management systems, risk management services and software related
to trade reconciliation, treasury, margin, financial and counterparty management, risk monitoring,
performance reporting, valuation quotation services (e.g., Bloomberg terminals, historical and live
financial data and other similar services and data feeds) and trade order management systems
(including systems that facilitate trade compliance, commission management, stock locates and
transaction cost analysis, and third party service providers used for implementation, custom
reporting, updates, consultations, support, maintenance, monitoring and data extracts); (iii) the
Funds’ legal, accounting, tax preparation and other tax-related expenses (including preparation
and mailing costs of financial statements, tax returns and other reports to Members), auditing,
consulting and other professional expenses, including any fees paid to third party valuation agents;
(iv) third-party administration costs and costs of outsourced Chief Compliance Officer, Chief
Financial Officer and Chief Operating Officer services, fees and expenses (including any costs,
fees and expenses related to investor communications, relations, reporting or other investor
materials, tax preparation and related reporting, performance information, data extraction and
other types of reporting and any audit or accounting services provided by a third-party
administrator) and directors’ fees and expenses, including, but not limited to, travel-related costs
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/26/2026) [Brochure]
Item 7: Types of Clients

GordonMD provides investment advisory services to the Funds. Investors in the Funds are required
to meet certain eligibility and suitability qualifications and make certain representations prior to
investing in a Fund. Subscription minimums are disclosed in the relevant Fund’s offering
documents (although GordonMD maintains the discretion to accept less than any minimum
investment commitment).

Each of the Funds may enter into agreements, or “side letters,” with certain prospective or existing
Fund investors whereby such investors, including such persons that may be affiliated with
GordonMD or its related persons, may be subject to terms and conditions that are more
advantageous than those set forth in the offering memorandum for the Fund. For example, such
terms and conditions may provide for special rights to make future investments in the Funds, other
investment vehicles or managed accounts, special redemption rights (including those relating to
frequency or notice),; a waiver or rebate in fees or redemption penalties to be paid by the and/or
other terms, rights to receive reports from the Fund on a more frequent basis or that include
information not provided to other investors (including, without limitation, more detailed
information regarding portfolio positions) and such other rights as may be negotiated by the
GordonMD and such investors. The modifications are solely at the discretion of the GordonMD
and may, among other things, be based on the size of the investor’s investment in the Fund, an
agreement by an investor to maintain such investment in the Fund for a significant period, or other
similar commitment by an investor to the Fund.
Sector Form 13F Holdings Value ($M)
Teva Pharmaceutical Industries Ltd 37.9
Kyverna Therapeutics Inc 36.6
VIR Biotechnology Inc 13.6
Bausch & LOMB Corp 9.1
Amgen Inc 7.1
Scholar Rock Holding Corp 6.5
Ultragenyx Pharmaceutical Inc 6.1
Pyxis Oncology Inc 6.0
Sionna Therapeutics Inc 5.5
Celldex Therapeutics Inc 5.4
View All
Holdings by Sector ($M)
16012896643202025202520262027
Type Form D Funds Date Sold AUM
PE Gordonmd SPV I LLC [2026-03-26] 22.5 M 5.0 M
Filed 2025-09-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE Gordonmd PE Fund II LP [2025-03-25] 26.6 M 19.3 M
Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
HF Gordonmd Long Biased Master Fund LP [2022-04-12] 84.5 M 202.0 M
Filed 2025-09-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Gordonmd PE Fund LP [2022-04-12] 0.7 M 96.0 M
Filed 2021-10-07 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $20,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 7 322.3
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 7 322.3
By Discretionary
Discretionary 7 322.3
Non-Discretionary 0 0.0
Total 7 322.3
By Non-United States Persons
Non-United States Persons 6.7
United States Persons 315.5
Total 7 322.3
Form D Directors Role # Filings # Firms 2011 - 2026
Tyler Stowater Executive Officer 58 3
Steve Kirby Executive Officer 43 3
Sandy Horst Executive Officer 21 3
Nikole Mulder Executive Officer 18 3
Jon Kirby Executive Officer 16 3
LLC Bluestem Capital Company Executive Officer 10 3
Andrew Doshier Executive Officer 6 3
Gordonmd Global Investments LP Executive Officer 7 2
Gordonmd Pe Fund II GP LLC Executive Officer 2 2
Gordonmd SPV Managing Member LLC Executive Officer 1 1
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0002039349]
3 [0002039349]
SC 13G [0002039349]
Form 13D/13G Filer Form 13D/13G Subject Filed
Gordonmd Global Investments LP Kyverna Therapeutics Inc [2025-11-17]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI2549000G7FOOABJP8C67
Comparable Firms State AUM
Triatomic Management LP
CA 346.3 M
Vedanta Management LP
NY 345.6 M
Borderless Management LLC
FL 345.4 M
Superstring Capital Management LP
NY 339.5 M
North Run Capital LP
MA 334.5 M
Opus Investment Management LLC
NY 331.9 M
Wolf River Capital Management LLC
TN 328.7 M
Talara Capital Management LLC
NJ 317.6 M
Spring Mountain Capital LP
NY 310.9 M
Coltrane Asset Management LP
NY 304.0 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com